A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression.

Johannes T Reckweg,Cees J van Leeuwen,Cécile Henquet,Therese van Amelsvoort,Eef L Theunissen,Natasha L Mason,Riccardo Paci,Theis H Terwey,Johannes G Ramaekers

Frontiers in psychiatry（2023）

引用 2|浏览16

暂无评分

摘要

Administration of GH001 to a cohort of 16 patients with TRD was well tolerated and provided potent and ultra-rapid antidepressant effects. Individualized dosing with up to three doses of GH001 on a single day was superior to single dose administration.: Clinicaltrials.gov Identifier NCT04698603.

查看译文

关键词

psychedelics, 5-MeO-DMT, treatment-resistant depression, individualized dosing, clinical trial

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要